vs

Side-by-side financial comparison of QVC Group, Inc. (QVCGA) and Steris (STE). Click either name above to swap in a different company.

QVC Group, Inc. is the larger business by last-quarter revenue ($2.7B vs $1.5B, roughly 1.8× Steris). Steris runs the higher net margin — 12.9% vs -1.4%, a 14.3% gap on every dollar of revenue. On growth, Steris posted the faster year-over-year revenue change (9.2% vs -9.1%). Steris produced more free cash flow last quarter ($199.5M vs $191.0M). Over the past eight quarters, Steris's revenue compounded faster (15.8% CAGR vs 6.9%).

QVC Group, is an American media conglomerate controlled by company chairman John C. Malone, who owns a majority of the voting shares.

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

QVCGA vs STE — Head-to-Head

Bigger by revenue
QVCGA
QVCGA
1.8× larger
QVCGA
$2.7B
$1.5B
STE
Growing faster (revenue YoY)
STE
STE
+18.3% gap
STE
9.2%
-9.1%
QVCGA
Higher net margin
STE
STE
14.3% more per $
STE
12.9%
-1.4%
QVCGA
More free cash flow
STE
STE
$8.5M more FCF
STE
$199.5M
$191.0M
QVCGA
Faster 2-yr revenue CAGR
STE
STE
Annualised
STE
15.8%
6.9%
QVCGA

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
QVCGA
QVCGA
STE
STE
Revenue
$2.7B
$1.5B
Net Profit
$-37.0M
$192.9M
Gross Margin
32.9%
43.8%
Operating Margin
3.7%
18.3%
Net Margin
-1.4%
12.9%
Revenue YoY
-9.1%
9.2%
Net Profit YoY
97.1%
11.2%
EPS (diluted)
$-17.37
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
QVCGA
QVCGA
STE
STE
Q4 25
$2.7B
$1.5B
Q3 25
$2.2B
$1.5B
Q2 25
$2.2B
$1.4B
Q1 25
$2.1B
$1.5B
Q4 24
$2.9B
$1.4B
Q3 24
$2.3B
$1.3B
Q2 24
$2.4B
$1.3B
Q1 24
$2.3B
$1.1B
Net Profit
QVCGA
QVCGA
STE
STE
Q4 25
$-37.0M
$192.9M
Q3 25
$-80.0M
$191.9M
Q2 25
$-2.2B
$177.4M
Q1 25
$-100.0M
$145.7M
Q4 24
$-1.3B
$173.5M
Q3 24
$-23.0M
$150.0M
Q2 24
$20.0M
$145.4M
Q1 24
$-1.0M
$-1.4M
Gross Margin
QVCGA
QVCGA
STE
STE
Q4 25
32.9%
43.8%
Q3 25
34.0%
44.2%
Q2 25
36.4%
45.1%
Q1 25
34.2%
43.3%
Q4 24
33.3%
44.5%
Q3 24
35.3%
43.6%
Q2 24
36.4%
44.7%
Q1 24
35.5%
40.2%
Operating Margin
QVCGA
QVCGA
STE
STE
Q4 25
3.7%
18.3%
Q3 25
2.7%
18.2%
Q2 25
-101.6%
17.7%
Q1 25
0.7%
14.6%
Q4 24
-43.2%
17.9%
Q3 24
6.5%
16.5%
Q2 24
6.9%
14.5%
Q1 24
6.2%
22.0%
Net Margin
QVCGA
QVCGA
STE
STE
Q4 25
-1.4%
12.9%
Q3 25
-3.6%
13.1%
Q2 25
-99.4%
12.8%
Q1 25
-4.8%
9.8%
Q4 24
-43.7%
12.7%
Q3 24
-1.0%
11.3%
Q2 24
0.8%
11.4%
Q1 24
-0.0%
-0.1%
EPS (diluted)
QVCGA
QVCGA
STE
STE
Q4 25
$-17.37
$1.96
Q3 25
$-9.89
$1.94
Q2 25
$-275.46
$1.79
Q1 25
$-0.25
$1.48
Q4 24
$1.75
Q3 24
$-0.06
$1.51
Q2 24
$2.57
$1.46
Q1 24
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
QVCGA
QVCGA
STE
STE
Cash + ST InvestmentsLiquidity on hand
$2.0B
$423.7M
Total DebtLower is stronger
$790.0M
$1.9B
Stockholders' EquityBook value
$-3.1B
$7.2B
Total Assets
$7.6B
$10.6B
Debt / EquityLower = less leverage
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
QVCGA
QVCGA
STE
STE
Q4 25
$2.0B
$423.7M
Q3 25
$1.8B
$319.2M
Q2 25
$897.0M
$279.7M
Q1 25
$833.0M
$171.7M
Q4 24
$905.0M
$155.2M
Q3 24
$873.0M
$172.2M
Q2 24
$1.2B
$198.3M
Q1 24
$1.1B
$207.0M
Total Debt
QVCGA
QVCGA
STE
STE
Q4 25
$790.0M
$1.9B
Q3 25
$5.9B
$1.9B
Q2 25
$4.9B
$1.9B
Q1 25
$5.0B
$1.9B
Q4 24
$4.1B
$2.0B
Q3 24
$5.1B
$2.2B
Q2 24
$5.3B
$2.2B
Q1 24
$5.5B
$3.1B
Stockholders' Equity
QVCGA
QVCGA
STE
STE
Q4 25
$-3.1B
$7.2B
Q3 25
$-3.1B
$7.0B
Q2 25
$-3.0B
$7.0B
Q1 25
$-981.0M
$6.6B
Q4 24
$-971.0M
$6.4B
Q3 24
$397.0M
$6.6B
Q2 24
$328.0M
$6.4B
Q1 24
$255.0M
$6.3B
Total Assets
QVCGA
QVCGA
STE
STE
Q4 25
$7.6B
$10.6B
Q3 25
$7.6B
$10.4B
Q2 25
$6.7B
$10.4B
Q1 25
$9.0B
$10.1B
Q4 24
$9.2B
$10.0B
Q3 24
$10.8B
$10.2B
Q2 24
$10.9B
$10.1B
Q1 24
$11.0B
$11.1B
Debt / Equity
QVCGA
QVCGA
STE
STE
Q4 25
0.27×
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.29×
Q4 24
0.32×
Q3 24
12.74×
0.33×
Q2 24
16.28×
0.35×
Q1 24
21.53×
0.50×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
QVCGA
QVCGA
STE
STE
Operating Cash FlowLast quarter
$244.0M
$298.2M
Free Cash FlowOCF − Capex
$191.0M
$199.5M
FCF MarginFCF / Revenue
7.1%
13.3%
Capex IntensityCapex / Revenue
2.0%
6.6%
Cash ConversionOCF / Net Profit
1.55×
TTM Free Cash FlowTrailing 4 quarters
$118.0M
$917.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
QVCGA
QVCGA
STE
STE
Q4 25
$244.0M
$298.2M
Q3 25
$4.0M
$287.8M
Q2 25
$86.0M
$420.0M
Q1 25
$-60.0M
$260.8M
Q4 24
$212.0M
$332.8M
Q3 24
$20.0M
$250.7M
Q2 24
$267.0M
$303.7M
Q1 24
$26.0M
$254.8M
Free Cash Flow
QVCGA
QVCGA
STE
STE
Q4 25
$191.0M
$199.5M
Q3 25
$-27.0M
$201.3M
Q2 25
$48.0M
$326.4M
Q1 25
$-94.0M
$189.9M
Q4 24
$150.0M
$243.6M
Q3 24
$-23.0M
$148.8M
Q2 24
$213.0M
$195.7M
Q1 24
$-14.0M
$163.3M
FCF Margin
QVCGA
QVCGA
STE
STE
Q4 25
7.1%
13.3%
Q3 25
-1.2%
13.8%
Q2 25
2.1%
23.5%
Q1 25
-4.5%
12.8%
Q4 24
5.1%
17.8%
Q3 24
-1.0%
11.2%
Q2 24
8.8%
15.3%
Q1 24
-0.6%
14.6%
Capex Intensity
QVCGA
QVCGA
STE
STE
Q4 25
2.0%
6.6%
Q3 25
1.4%
5.9%
Q2 25
1.7%
6.7%
Q1 25
1.6%
4.8%
Q4 24
2.1%
6.5%
Q3 24
1.8%
7.7%
Q2 24
2.2%
8.4%
Q1 24
1.7%
8.2%
Cash Conversion
QVCGA
QVCGA
STE
STE
Q4 25
1.55×
Q3 25
1.50×
Q2 25
2.37×
Q1 25
1.79×
Q4 24
1.92×
Q3 24
1.67×
Q2 24
13.35×
2.09×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

QVCGA
QVCGA

Other$915.0M34%
Home$754.0M28%
Beauty$260.0M10%
Apparel$254.0M9%
Electronics$187.0M7%
Accessories$181.0M7%
Jewelry$87.0M3%
Manufactured Product Other$38.0M1%

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

Related Comparisons